{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T17:34:53Z","timestamp":1740159293220,"version":"3.37.3"},"reference-count":14,"publisher":"FapUNIFESP (SciELO)","issue":"2","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Bras. Nefrol."],"abstract":"<jats:p>Abstract  Introduction: Hyperphosphatemia is a serious consequence of chronic kidney disease and has been associated with an increased risk for cardiovascular disease. Controlling serum phosphorus levels in patients on dialysis is a challenge for the clinicians and implies, in most cases, the use of phosphate binders (PB). Part of the reason for this challenge is poor adherence to treatment because of the high pill burden in this patient group.  Objective: To assess the real-world effectiveness of sucroferric oxyhydroxide (SO) in controlling serum phosphorus levels and determine the associated pill burden.  Methods: A multicenter, quantitative, retrospective, before-after study was conducted with patients receiving online hemodiafiltration. Patients who switched to SO as a part of routine care were included in the study. PB treatment, number of pills, serum phosphorus levels, and intravenous iron medication and dosage were collected monthly during the six months of treatment with either PB or SO.  Results: A total of 42 patients were included in the study. After switching from a PB to SO, the prescribed pills\/day was reduced 67% from 6 pills\/day to 2 pills\/day (p &lt; 0.001) and the frequency of pill intake was lowered from 3 times\/day to 2 times\/day (p &lt; 0.001). During the treatment with SO, the proportion of patients with serum phosphorus \u2264 5.5 mg\/dL increased from 33.3% at baseline to 45% after six months of treatment.  Conclusion: During the six-month follow-up with SO, serum phosphorus levels were controlled with one third of the pills\/day compared to other PB.<\/jats:p>","DOI":"10.1590\/2175-8239-jbn-2018-0142","type":"journal-article","created":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T15:18:31Z","timestamp":1549379911000},"page":"224-230","source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness of sucroferric oxyhydroxide in patients on on-line hemodiafiltration in real-world clinical practice: A retrospective study"],"prefix":"10.1590","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3300-6033","authenticated-orcid":false,"given":"An\u00edbal","family":"Ferreira","sequence":"first","affiliation":[{"name":"Universidade Nova de Lisboa,  Portugal; NephroCare Vila Franca de Xira,  Portugal"}]},{"given":"Bruno","family":"Pinto","sequence":"additional","affiliation":[{"name":"NephroCare Portugal,  Portugal"}]},{"given":"David","family":"Navarro","sequence":"additional","affiliation":[{"name":"NephroCare Vila Franca de Xira,  Portugal"}]},{"given":"Jo\u00e3o","family":"Aniceto","sequence":"additional","affiliation":[{"name":"NephroCare \u00c9vora,  Portugal"}]},{"given":"Pedro L","family":"Neves","sequence":"additional","affiliation":[{"name":"Centro Hospitalar Universit\u00e1rio do Algarve,  Portugal"}]},{"given":"Pedro","family":"Ponce","sequence":"additional","affiliation":[{"name":"NephroCare Lumiar,  Portugal; NephroCare Portugal,  Portugal"}]}],"member":"530","published-online":{"date-parts":[[2019,6]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40620-016-0266-9","article-title":"Phosphate binders in chronic kidney disease: a systematic review of recent data","volume":"29","author":"Floege J","year":"2016","journal-title":"J Nephrol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.aogh.2013.12.007","article-title":"Cardiovascular pathophysiology in chronic kidney disease: opportunities to transition from disease to health","volume":"80","author":"Tomey MI","year":"2014","journal-title":"Ann Glob Health"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","volume":"7","year":"2017","journal-title":"Kidney Int Suppl"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/ki.2013.185","article-title":"Use of phosphate-binding agents is associated with a lower risk of mortality","volume":"84","author":"Cannata-And\u00eda JB","year":"2013","journal-title":"Kidney Int"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(13)60897-1","article-title":"Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis","volume":"382","author":"Jamal SA","year":"2013","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2215\/CJN.03820411","article-title":"Mortality in kidney disease patients treated with phosphate binders: a randomized study","volume":"7","author":"Di Iorio B","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2215\/CJN.00290109","article-title":"Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients","volume":"4","author":"Chiu YW","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/ndt\/gft280","article-title":"Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis","volume":"29","author":"Wang S","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5414\/CNP74004","article-title":"PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease","volume":"74","author":"Geisser P","year":"2010","journal-title":"Clin Nephrol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/ndt\/gfv006","article-title":"Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients","volume":"30","author":"Floege J","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","article-title":"A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients","volume":"86","author":"Floege J","year":"2014","journal-title":"Kidney Int"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2215\/CJN.08230811","article-title":"Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients","volume":"8","author":"W\u00fcthrich RP","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40620-014-0080-1","article-title":"Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects","volume":"27","author":"Chong E","year":"2014","journal-title":"J Nephrol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/ndt\/gfw460","article-title":"One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis","volume":"32","author":"Floege J","year":"2017","journal-title":"Nephrol Dial Transplant"}],"container-title":["Brazilian Journal of Nephrology"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/jbn\/v41n2\/2175-8239-jbn-2018-0142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T15:50:56Z","timestamp":1581090656000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0101-28002019000200224&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":14,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["S0101-28002019000200224"],"URL":"https:\/\/doi.org\/10.1590\/2175-8239-jbn-2018-0142","relation":{},"ISSN":["2175-8239","0101-2800"],"issn-type":[{"type":"electronic","value":"2175-8239"},{"type":"print","value":"0101-2800"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}